<DOC>
	<DOCNO>NCT02827903</DOCNO>
	<brief_summary>Compare Efficacy Safety Metformin/Rosuvastatin Combination Therapy With Metformin Rosuvastatin Monotherapy Patients With Type 2 Diabetes Dyslipidemia</brief_summary>
	<brief_title>Metformin/Rosuvastatin Combination Therapy With Patients With Type 2 Diabetes Dyslipidemia</brief_title>
	<detailed_description>Multi-center , Randomized , Double-blind , Phase III clinical trial</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Over 19 year Type II DM Dyslipidemia 6.5 % ≤ HbA1c &lt; 11 % Triglyceride &lt; 350mg/dL 100mg/dL ≤ LDLC ≤ 250mg/dL FPG ≤ 270mg/dL Type I DM Unstable angina , MI , Stroke , CABG 6 month screen SBP ≥ 180mmHg , DBP ≥ 110mmHg TSH &gt; UNL Heart failure ( NYHA class III/IV ) Serum Creatinine &gt; UNL CLCr &lt; 60 mL/min CK ≥ 2x UNL HIV positive BMI &gt; 40 kg/m^2</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Metformin</keyword>
	<keyword>Rosuvastatin</keyword>
	<keyword>type 2 diabetes</keyword>
	<keyword>dyslipidemia</keyword>
</DOC>